Gerardo Guilarte

Gerardo Guilarte

Auto-generated profile, based on publicly available information

Gerardo Guilarte

Department of Dermatology University of Pittsburgh Medical Center Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
NANana-Hawwa Abdul-Rahman
Nana-Hawwa Abdul-Rahman
ALAlice D. Lee
Alice D. Lee
GGGerardo Guiltarte
Gerardo Guiltarte
SCSonal Choudhary
Sonal Choudhary
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by epidermal barrier dysfunction, immune dysregulation, and intense pruritus. Although existing treatments, including topical corticosteroids, calcineurin inhibitors, and biologic agents, are effective for many patients, concerns regarding long‐term safety, cost, and incomplete disease control have driven interest in nonimmunosuppressive and complementary therapeutic strategies. L‐histidine is an essential dietary amino acid that has emerged as a potential biologic modulator in AD due to its central role in filaggrin metabolism and natural moisturizing factor (NMF) production. This narrative review synthesizes the current mechanistic, preclinical, and clinical evidence evaluating L‐histidine as a therapeutic or adjunctive intervention in AD. L‐histidine supports epidermal hydration, pH homeostasis, and barrier integrity through its role as a precursor of filaggrin‐derived NMF components. In vitro and skin‐equivalent models demonstrate that L‐histidine enhances filaggrin processing and improves functional barrier properties. Importantly, mechanistic studies indicate that histidine supplementation does not promote pathological histamine production, alleviating concerns regarding histamine‐mediated disease exacerbation. Clinical evidence, though limited to small exploratory trials and case reports, shows reductions in disease severity and pruritus in both pediatric and adult patients receiving oral L‐histidine supplementation. However, these findings should be regarded as preliminary rather than conclusive. The magnitude of improvement reported in these small trials has been described by the authors as similar to SCORAD reductions historically reported for mid‐potency topical corticosteroids. However, this is a benchmark comparison against external historical literature, not a head‐to‐head assessment. Since no head‐to‐head trial has directly compared L‐histidine with topical corticosteroids, its efficacy should not be considered equivalent or directly comparable to that of topical corticosteroids. Oral L‐histidine has demonstrated a favorable safety and tolerability profile to date, with no serious adverse events reported. L‐histidine is a low‐cost, well‐tolerated, barrier‐targeted adjunct with potential utility in AD management. Larger, long‐term randomized controlled trials incorporating genetic stratification and combination therapy designs are warranted to better define its optimal role in clinical practice.

9 November 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
RPReethi Padmanabhan
Reethi Padmanabhan
CGConnor Gill
Connor Gill
LJLucie Joerg
Lucie Joerg
MMMiriam Motlak
Miriam Motlak
GGGerardo Guilarte
Gerardo Guilarte
SCSonal Choudhary
Sonal Choudhary
Background: Topical peptides have emerged as a promising cosmeceutical for indications ranging from hyperpigmentation to anti‐aging. However, their role in post‐procedural wound healing following aesthetic interventions remains underexplored. Aims: The aim of this study was to systematically evaluate the evidence supporting the use of topical peptide formulations in enhancing post‐procedural wound healing and patient recovery outcomes. Methods: A systematic review was conducted to identify clinical studies evaluating topical peptide application following aesthetic dermatologic procedures, including radiofrequency microneedling and non‐ablative laser therapies. Eligible studies assessed both cosmetic and therapeutic outcomes related to wound healing and recovery. Results: Six studies met inclusion criteria across three peptide systems and across ablative laser, nonablative laser, hybrid laser, and radiofrequency microneedling procedures. Peptide formulations following ablative procedures were associated with improvements in exudation, crusting, and epithelial confluence, whereas nonablative procedures demonstrated reduced erythema and improved patient‐reported recovery outcomes, including enhanced skin appearance and texture. Studies of hybrid fractional resurfacing and radiofrequency microneedling similarly reported improvements in selected early recovery outcomes. Conclusion: Topical peptide formulations show potential as adjunctive therapies for improving post‐procedural recovery following aesthetic dermatologic procedures. However, available evidence is limited by varying procedural modalities, small sample sizes, short follow‐up intervals, and restricted demographic diversity. Larger randomized controlled trials with broader representation across Fitzpatrick skin types are necessary to better define the clinical role of topical peptide cosmeceuticals in post‐procedural wound healing.

11 November 2026 in JAAD Reviews
Verified
Journal Article
Open access
GGGerardo Guilarte
Gerardo Guilarte
CGConnor Gill
Connor Gill
SKShayan Khwaja
Shayan Khwaja
DLDongwon Lee
Dongwon Lee
LJLucie Joerg
Lucie Joerg
SCSonal Choudhary
Sonal Choudhary

8 April 2026 in JAAD Reviews
Verified
Journal Article
Open access
GGGerardo Guilarte
Gerardo Guilarte
JPJanmesh D. Patel
Janmesh D. Patel
DLDongwon Lee
Dongwon Lee
SCSonal Choudhary
Sonal Choudhary

29 June 2026 in JAAD Reviews
Verified
Journal Article
Open access
GGGerardo Guilarte
Gerardo Guilarte
CGConnor Gill
Connor Gill
LJLucie Joerg
Lucie Joerg
DLDongwon Lee
Dongwon Lee
SKShayan Khwaja
Shayan Khwaja
SCSonal Choudhary
Sonal Choudhary

18 April 2026 in Journal of Pediatric Health Care
Verified
Journal Article
Closed access
LGLillybet Guilarte
Lillybet Guilarte
GGGerardo Guilarte
Gerardo Guilarte
LVLourdes Valdes-Fernandez
Lourdes Valdes-Fernandez